Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14484MR)

This product GTTS-WQ14484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12344MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ2057MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ6772MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ8121MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ827MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ9715MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ15027MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ4568MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.